TrialBMJ (Clinical research ed.)2022

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.

Zhihao Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.